A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

The incidence of HER2 somatic mutations in breast cancer is about 2–4%, mainly occurring in the HR+/HER2- subtype. Preclinical studies suggest that HER2 mutations can lead to constitutive HER2 activation, but effective treatment options for the clinical management of patients with HER2 mutations rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jing, Li, Xuelu, Zhang, Qianran, Li, Ning, Sun, Siwen, Zhao, Shanshan, Zhao, Zuowei, Li, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079719/
https://www.ncbi.nlm.nih.gov/pubmed/35523006
http://dx.doi.org/10.1016/j.tranon.2022.101444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079719/
https://www.ncbi.nlm.nih.gov/pubmed/35523006
http://dx.doi.org/10.1016/j.tranon.2022.101444

Ejemplares similares